MyeloPro is a research stage biopharmaceutical company, aiming to develop innovative therapeutics for the treatment of blood diseases/myeloproliferative neoplasms (MPNs). MyeloPro’s research focuses on the development of antibodies that target the mutated form of the protein called calreticulin (CALR).

www.myelopro.com